InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. (IN.TO) Financial Performance & Income Statement Overview
Analyze InMed Pharmaceuticals Inc. (IN.TO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
InMed Pharmaceuticals Inc. (IN.TO) Income Statement & Financial Overview
Analyze InMed Pharmaceuticals Inc.’s IN.TO earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $1.11B | $1.26M | $1.28M | $1.17M |
| Cost of Revenue | $650.81M | $771225.00 | $6.99B | $1.03M |
| Gross Profit | $460.89M | $493413.00 | -$6.99B | $139076.00 |
| Gross Profit Ratio | $0.41 | $0.39 | -$5446.90 | $0.12 |
| R&D Expenses | $1.06B | $771180.00 | $1.21M | $656764.00 |
| SG&A Expenses | $1.55B | $1.42M | $1.21M | $1.28M |
| Operating Expenses | $2.61B | $493413.00 | $466071.00 | $1.94M |
| Total Costs & Expenses | $3.26B | $1.26M | $16.00B | $2.97M |
| Interest Income | $0.00 | $57094.00 | $103640.00 | $121458.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $53.20M | $144980.00 | $151861.00 | $150382.00 |
| EBITDA | -$2.10B | -$1.61M | -$2.04M | -$2.36M |
| EBITDA Ratio | -$1.89 | -$1.27 | -$1.59 | -$1.40 |
| Operating Income | -$2.15B | $0.00 | $0.00 | -$1.80M |
| Operating Income Ratio | -$1.94 | $0.00 | $0.00 | -$1.53 |
| Other Income/Expenses (Net) | -$421.97M | -$1.68M | -$1.93M | $99291.00 |
| Income Before Tax | -$2.58B | -$1.68M | -$1.93M | -$1.72M |
| Income Before Tax Ratio | -$2.32 | -$1.33 | -$1.50 | -$1.47 |
| Income Tax Expense | $0.00 | $0.00 | $7100.00 | -$3.00 |
| Net Income | -$2.58B | -$1.68B | -$1.94M | -$1.72M |
| Net Income Ratio | -$2.32 | -$1326.76 | -$1.51 | -$1.47 |
| EPS | -$3.64 | -$2.71 | -$0.22 | -$0.24 |
| Diluted EPS | -$3.64 | -$2.71 | -$0.22 | -$0.24 |
| Weighted Avg Shares Outstanding | $7.07M | $6.20M | $8.92M | $9.61M |
| Weighted Avg Shares Outstanding (Diluted) | $7.07M | $6.20M | $8.92M | $9.61M |
Financial performance has remained strong, with revenue growing from $1.17M in Q3 2024 to $1.11B in Q2 2025. Gross profit continued to perform well, with margins at 41% in the latest quarter. Operating income reached -$2.15B in Q2 2025, holding a steady -194% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$2.10B. Net income dropped to -$2.58B, keeping EPS at -$3.64. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan